Detralex® (Detralex®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsporal suspension
Composition:

Composition on 1 sachet (10 ml):

Active substance: Purified micronized flavonoid fraction 1000 mg, containing diosmin 900.0 mg (90%) and flavonoids, calculated on hesperidin 100.0 mg (10%).

Excipients: Citric acid 12.5 mg, orange flavoring 15.0 mg, maltitol 1800.0 mg, sodium benzoate 15.0 mg, xanthan gum 50.0 mg, purified water q.s. up to 10 ml.

Description:Homogeneous suspension of light yellow color with a characteristic odor.
Pharmacotherapeutic group:Venotonizing and venoprotective agent
ATX: & nbsp
  • Diosmin in combination with other drugs
    • Pharmacodynamics:

    Detralex® has venotonic and angioprotective properties. The drug reduces the extensibility of veins and venous congestion, reduces the permeability of capillaries and increases their resistance. results clinical studies confirm the pharmacological activity of the drug with respect to the indices of venous hemodynamics.

    The statistically significant dose-dependent effect of Detralex® was demonstrated for the following venous plethysmographic parameters: venous capacity, venous dilatability, venous emptying time.The optimal "dose-effect" ratio is observed when taking 1000 mg per day.

    Detralex® increases the venous tone: a decrease in the time of venous emptying has been shown with venous occlusion plethysmography. In patients with signs of severe disturbance of microcirculation, after treatment with Detralex®, there is a (statistically significant compared with placebo) increase in capillary resistance, estimated by angiostereiometry. The therapeutic effectiveness of Detralex ® in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids, is proved.

    Detralex® reduces the undesirable side effects of invasive procedures for Chlamydia (reduces the incidence of undesirable side effects in surgical and endovascular treatment of varicose veins: significantly reduces the intensity of postoperative pain syndrome, edema and severity of hemorrhages after endovascular and surgical treatment).

    Pharmacokinetics:

    The main release of the drug occurs with feces. With urine, on average, about 14% of the taken amount of the drug is excreted.

    The half-life is 11 hours.

    The drug is subject to active metabolism, which is confirmed by the presence of phenolic acids in the urine.

    Indications:

    Detralex® is indicated for the treatment of symptoms of chronic venous diseases (elimination and alleviation of symptoms).

    Therapy of symptoms of venous-lymphatic insufficiency:

    - pain;

    - convulsions of the lower limbs;

    - Feeling of heaviness and raspiraniya in the legs;

    - "fatigue" of the feet.

    Therapy of manifestations of venous-lymphatic insufficiency:

    swelling of the lower extremities;

    - trophic changes in the skin and subcutaneous tissue; Venous trophic ulcers.

    Symptomatic therapy of acute and chronic hemorrhoids.
    Contraindications:

    Hypersensitivity to the active substance or to the excipients included in the preparation.

    Intolerance to fructose.

    It is not recommended to take the drug for lactating women.

    Pregnancy and lactation:

    Pregnancy

    Experiments on animals did not reveal teratogenic effects.

    To date, there have been no reports of undesirable effects in the use of the drug by pregnant women.

    Breastfeeding period

    Due to the lack of data on the excretion of the drug with breast milk, lactating women are not recommended taking the drug.

    Influence on reproductive function

    Reproductive toxicity studies showed no effect on reproductive function in rats of both sexes.

    Dosing and Administration:

    Inside.

    The recommended dose for venous-lymphatic insufficiency - 1000 mg (contents of 1 sachet) per day, preferably in the morning, during meals.

    The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

    Recommended dose for acute hemorrhoids - 3000 mg per day (1000 mg (contents 1 sachet) in the morning, afternoon and evening) for 4 days, then 2000 mg per day (1000 mg (contents 1 sachet) in the morning and evening) for the next 3 days.

    Recommended dose for chronic hemorrhoids - 1000 mg (contents of 1 sachet) per day at any convenient time of the day, along with food intake.

    Side effects:

    The side effects of Detralex®, observed during clinical trials, were mild. Most noted violations of the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting).

    During the reception of Detralex®, the following side effects were reported, in the form of the following gradation: very often (> 1/10); often (> 1/100, <1/10); infrequently (> 1/1 000, <1/100); rarely (> 1/10 000, <1/1 000); extremely rare (<1/10 000), unspecified frequency (the frequency can not be calculated from the available data).

    From the central nervous system:

    Rarely: dizziness, headache, general malaise.

    From the gastrointestinal tract:

    Often: diarrhea, dyspepsia, nausea, vomiting.

    Infrequently: colitis.

    Unspecified frequency: abdominal pain.

    From the skin:

    Rarely: skin rash, itching, hives.

    Unspecified frequency: isolated edema of the face, lips, eyelids. AT exceptional cases of angioedema.

    Inform your doctor about the appearance YOU ALL, including those not mentioned in this manual, adverse reactions and sensations, as well as ON changes in laboratory parameters during therapy.

    Overdose:

    Cases of overdose are not described.

    If an overdose occurs, seek medical help immediately.

    Interaction:

    Not noted.

    Should inform your doctor about any decisions you Medicinal prepTAX.

    Special instructions:

    - Before taking Detralex®, it is recommended that you consult with your doctor.

    - With exacerbation of hemorrhoids, the purpose of Detralex® does not replace the specific treatment of other anal disorders. Duration of treatment should not exceed the time specified in the section "Method of administration and dose". In the event that the symptoms do not disappear after the recommended course of therapy, you should undergo an examination with a proctologist who will choose further therapy.

    In the presence of violations of venous circulation, the maximum effect of treatment is provided by combining therapy with a healthy (balanced) way of life; it is desirable to avoid a long stay in the sun, a prolonged stay on the legs, and also, it is recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings (compression jersey) contribute to improving blood circulation.

    Immediately consult a doctor if your condition worsens during treatment or there is no improvement.

    Effect on the ability to drive transp. cf. and fur:

    Does not affect.

    Form release / dosage:Suspension for oral administration, 1000 mg / 10 ml.
    Packaging:

    For 10 ml of suspension for ingestion in multilayer sachets (polyester, aluminum, polyethylene).For 15 or 30 sachets, along with instructions for medical use in a pack of cardboard.

    Storage conditions:

    Store at a temperature not exceeding 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date stated on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-004247
    Date of registration:17.04.2017
    Expiration Date:17.04.2022
    The owner of the registration certificate:Servier LaboratoriesServier Laboratories France
    Manufacturer: & nbsp
    Representation: & nbspServier Laboratories Servier Laboratories France
    Information update date: & nbsp12.05.2017
    Illustrated instructions
      Instructions
      Up